Literature DB >> 2297605

Schneider's first-rank symptoms of schizophrenia: prevalence and diagnostic use. A study from Pakistan.

S B Malik1, M Ahmed, A Bashir, T M Choudhry.   

Abstract

The prevalence of Schneiderian first-rank symptoms in 75 schizophrenic in-patients was found to be 67%. The commonest were somatic passivity, thought broadcast, and thought insertion. This suggests a considerable variation in the prevalence of first-rank symptoms and their individual frequencies in different cultures. First-rank symptoms thus have inherent weaknesses.

Entities:  

Mesh:

Year:  1990        PMID: 2297605     DOI: 10.1192/bjp.156.1.109

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  5 in total

Review 1.  First rank symptoms for schizophrenia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman; Clare Davenport; Amanda J Kirkham; Sarah Grabowski; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-01-25

Review 2.  The Prehistory of Schneider's First-Rank Symptoms: Texts From 1810 to 1932.

Authors:  Kenneth S Kendler; Aaron Mishara
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

3.  The special treatment of first rank auditory hallucinations and bizarre delusions in the diagnosis of schizophrenia.

Authors:  Ann K Shinn; Stephan Heckers; Dost Öngür
Journal:  Schizophr Res       Date:  2013-03-22       Impact factor: 4.939

Review 4.  The diagnostic status of first-rank symptoms.

Authors:  Julie Nordgaard; Sidse M Arnfred; Peter Handest; Josef Parnas
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

5.  Investigating the relationship between thought interference, somatic passivity and outcomes in patients with psychosis: a natural language processing approach using a clinical records search platform in south London.

Authors:  Thibault Thierry Magrangeas; Anna Kolliakou; Jyoti Sanyal; Rashmi Patel; Robert Stewart
Journal:  BMJ Open       Date:  2022-08-02       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.